News Keros pulls study of Winrevair rival after safety signal Adverse events have led Keros to abandon a phase 2 trial of pulmonary arterial hypertension drug cibotacept, a would-be rival to MSD's Winrevair.
News Safety fear halts Keros PAH trial dosing, hitting its shares An unexpected side effect has led Keros to halt dosing in two arms of its phase 2 trial of pulmonary arterial hypertension drug cibotercept.
News Nine more companies sign pricing deals with Trump Nine more pharma groups have agreed to lower the costs of medicines in the US under the Trump administration's most favoured nation (MFN) scheme.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.